TITLE

Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study

AUTHOR(S)
van Eijk, J. J. J.; van Alfen, N.; Berrevoets, M.; van der Wilt, G. J.; S Pillen; van Engelen, B. G. M.
PUB. DATE
October 2009
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Oct2009, Vol. 80 Issue 10, p19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Effective treatment for neuralgic amyotrophy (NA), a disabling brachial plexus syndrome of supposed immunomediated origin, is currently lacking. Given the circumstantial evidence of a beneficial effect of prednisolone on pain and paresis, this report evaluates the effects of prednisolone treatment administered in the acute phase in a retrospective case series of 50 NA patients. Methods: Baseline variables (eg, age, sex, type of NA and number of attacks), treatment variables (eg, time until treatment, regimen and use of analgesics) and outcome measures (eg, duration and severity of pain, time course and severity of paresis and functional outcome) were statistically analysed and compared with a historical control group of 203 untreated NA patients. Results: The baseline characteristics of the two patient groups were comparable. The median time until initial pain relief was lower in the study group (12.5 days vs 20.5 days), and a significantly higher percentage already recovered strength in the first month of treatment (18% vs 6.3%; p = 0.011). Twelve per cent had fully recovered within 1 year, while this was 1% for the controls (p<0.001), with the proportion reporting a "good" 12-month outcome also being higher (44% vs 10.7%; p<0.001). Side effects were reported by 20%, but none led to a discontinuation of treatment. Conclusion: Oral prednisolone seems effective in the acute phase of neuralgic amyotrophy with the current results supporting previous case reports. A regimen of oral prednisolone is therefore recommended in the acute phase of the syndrome pending a prospective, randomised trial verifying the results obtained.
ACCESSION #
44721104

 

Related Articles

  • Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. Kleinschmidt-DeMasters, B.K.; Tyler, Kenneth L. // New England Journal of Medicine;7/28/2005, Vol. 353 Issue 4, p369 

    A 46-year-old woman with relapsing–remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after having received 37 doses of natalizumab (300 mg every four weeks) as part of a clinical trial of natalizumab and interferon beta-1a. PML was diagnosed on the...

  • Existing anticholinergics show few CNS effects. Bankhead, Charles // Urology Times;11/1/2004, Vol. 32 Issue 16, p17 

    Discusses the results of a randomized clinical trial about the incidence of adverse effects in anticholinergic drugs commonly used in the treatment of overactive bladder. Effects of the drugs in the central nervous system; Overall tolerance to extended-release formulations of oxybutynin and...

  • Ropivacaine.  // Reactions Weekly;12/15/2007, Issue 1182, p31 

    The article describes a case of ropivacaine-induced neurotoxicity in a 76-year-old woman who was being treated for brachial plexus block. The patient became unresponsive and had a generalised tonic-clonic seizure, fifteen minutes following the administration of 25 milligrams of ropivacaine. Her...

  • Post-op PCA adverse effects? Schechter, Leslie N. // Drug Topics;9/27/2004, Vol. 148 Issue 18, pHSE8 

    This article article presents two physicians' answers to a clinical question. The situation involved a woman who is hospitalized following a total abdominal hysterectomy. She has been using a meperidine patient-controlled analgesia (PCA) to control pain. She manifests agitation, irritability,...

  • Peripherally Restricted Opioid Agonists as Novel Analgesic Agents. DeHaven-Hudkins, D. L.; Dolle, R. E. // Current Pharmaceutical Design;Mar2004, Vol. 10 Issue 7, p743 

    Mediation of antinociception via opioid receptors located in the periphery is a viable strategy to produce analgesia without the occurrence of side effects associated with stimulation of opioid receptors located in the central nervous system. Peripheral opioid receptors are particularly...

  • Adverse reactions to new anticonvulsant drugs. Wong, I.C.K.; Lhatoo, S.D.; Wong, I C // Drug Safety;Jul2000, Vol. 23 Issue 1, p35 

    A lack of systematic pharmacoepidemiological studies investigating adverse drug reactions (ADRs) to anticonvulsants makes it difficult to assess accurately the incidence of anticonvulsant-related ADRs. Most of the available information in this regard stems from clinical trial experience, case...

  • CNS Drug Liabilities in Early Phase Clinical Trials. Schoedel, Kerri; Geoffroy, Pierre // Applied Clinical Trials;May2013, Vol. 22 Issue 5, p24 

    The article focuses on the lack of efficient drugs to treat Central Nervous System (CNS) diseases due to high adverse effect standards which are not met by CNS trials. It states that several challenges are faced while developing CNS drugs including the patient heterogeneity, need to cross the...

  • Update on the CNS Adverse Effects of Sustiva (Efavirenz).  // AIDS Alert;Mar2007, Vol. 22 Issue 3, p32 

    The article presents an update on the adverse effects of the Sustiva drug on the central nervous system.

  • Meperidine and Central Neurotoxicity. Hershey, Linda A. // Annals of Internal Medicine;Apr83, Vol. 98 Issue 4, p548 

    Discusses the effects of the narcotic analgesic meperidine on the central nervous system. Mechanism of action of the drug; Factors that predispose certain patients to adverse neurologic drug effects; Precautionary measures that physicians should take.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics